



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2553886 C 2014/08/05

(11)(21) **2 553 886**

(12) **BREVET CANADIEN  
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2005/01/27  
(87) Date publication PCT/PCT Publication Date: 2005/08/18  
(45) Date de délivrance/Issue Date: 2014/08/05  
(85) Entrée phase nationale/National Entry: 2006/07/20  
(86) N° demande PCT/PCT Application No.: EP 2005/000937  
(87) N° publication PCT/PCT Publication No.: 2005/074995  
(30) Priorité/Priority: 2004/01/28 (GB0401876.8)

(51) Cl.Int./Int.Cl. *A61K 48/00* (2006.01)  
(72) Inventeurs/Inventors:  
BERNARDS, RENE, NL;  
EPPING, MIRJAM, NL;  
WANG, LIMING, NL  
(73) Propriétaire/Owner:  
TOPOTARGET UK LIMITED, GB  
(74) Agent: SMART & BIGGAR

(54) Titre : UTILISATION COMBINEE D'INHIBITEURS DE PRAME ET DE HDAC  
(54) Title: COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS

(57) **Abrégé/Abstract:**

The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MELanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number  
**WO 2005/074995 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 48/00**

(74) Agents: **BRASNETT, Adrian** et al.; Mewburn Ellis LLP,  
York House, 23 Kingsway, London Greater London WC2B  
6HP (GB).

(21) International Application Number:  
PCT/EP2005/000937

(22) International Filing Date: 27 January 2005 (27.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0401876.8 28 January 2004 (28.01.2004) GB

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**VERENIGING HET NEDERLANDS KANKER  
INSTITUUT** [NL/NL]; Plesmanlaan 121, NL-1066 CX  
Amsterdam (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BERNARDS, René**  
[NL/NL]; Division of Molecular Carcinogenesis, The  
Netherlands Cancer Institute, Plesmanlaan 121, NL-1066  
CX Amsterdam (NL). **EPPING, Mirjam** [NL/NL];  
Division of Molecular Carcinogenesis, The Netherlands  
Cancer Institute, Plesmanlaan 121, NL-1066 CX Amster-  
dam (NL). **WANG, Liming** [CN/NL]; The Netherlands  
Cancer Institute, Plesmanlaan 121, NL-1066 CX Amster-  
dam (NL).

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS

(57) Abstract: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.

WO 2005/074995 A2

# **DEMANDES OU BREVETS VOLUMINEUX**

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS  
COMPREND PLUS D'UN TOME.**

**CECI EST LE TOME \_\_1\_\_ DE \_\_2\_\_**

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

---

# **JUMBO APPLICATIONS / PATENTS**

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE  
THAN ONE VOLUME.**

**THIS IS VOLUME \_\_1\_\_ OF \_\_2\_\_**

NOTE: For additional volumes please contact the Canadian Patent Office.

COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS

The present invention defines a new use for the known cancer antigen PRAME (PReferentially expressed Antigen in MElanoma), and in particular provides methods for the stratification of cancer patients based on PRAME expression and for the treatment of subjects with cancer by the inhibition of PRAME expression or activity.

Retinoic acid (RA) induces proliferation arrest, differentiation and apoptosis in a wide variety of cell types (Altucci, 2001; Freemantle, 2003). Defects in retinoic acid receptor (RAR) signalling, such as those caused by the PML-RAR $\alpha$  and PLZF-RAR $\alpha$  translocations in acute promyelocytic leukaemia, have been implicated in cancer (Altucci, 2001; Freemantle, 2003. Binding of RA to its receptor leads to release of co-repressor molecules and recruitment of co-activators to RAR, resulting in activation of transcription (Xu, 1999).

Acetylation and deacetylation of histones is associated with transcriptional events leading to cell proliferation and/or differentiation. Regulation of the function of transcription factors is also mediated through acetylation. Recent reviews of histone deacetylation include Kouzarides, 1999 and Pazin et al., 1997.

25

The correlation between the acetylation status of histones and the transcription of genes has been known for over 30 years (see, for example, Howe et al., 1999). Certain enzymes, specifically acetylases (e.g., histone acetyltransferase, HAT) and deacetylases (e.g., histone deacetylase, HDAC), which regulate the acetylation state of histones have been identified in many organisms and have been implicated in the regulation of numerous genes, confirming the link between acetylation and

30

transcription. See, for example, Davie, 1998. In general, histone acetylation correlates with transcriptional activation, whereas histone deacetylation is associated with gene repression.

5

A growing number of histone deacetylases (HDACs) have been identified (see, for example, Ng and Bird, 2000). The first deacetylase, HDAC1, was identified in 1996 (see, for example, Tauton et al., 1996). Subsequently, two other nuclear mammalian  
10 deacetylases were found, HDAC2 and HDAC3 (see, for example, Yang et al., 1996, 1997, and Emiliani et al., 1998). See also, Grozinger et al., 1999; Kao et al., 2000; and Van den Wyngaert et al., 2000.

15 HDACs function as part of large multiprotein complexes, which are tethered to the promoter and repress transcription. Well characterised transcriptional repressors such as Mad (Laherty et al., 1997), pRb (Brehm et al., 1998), nuclear receptors (Wong et al., 1998) and YY1 (Yang et al., 1997) associate with HDAC  
20 complexes to exert their repressor function.

The study of inhibitors of histone deacetylases indicates that these enzymes play an important role in cell proliferation and differentiation. The inhibitor Trichostatin A (TSA) (Yoshida et  
25 al., 1990a) causes cell cycle arrest at both G1 and G2 phases (Yoshida and Beppu, 1988), reverts the transformed phenotype of different cell lines, and induces differentiation of Friend leukaemia cells and others (Yoshida et al., 1990b). TSA (and SAHA) have been reported to inhibit cell growth, induce terminal  
30 differentiation, and prevent the formation of tumours in mice (Finnin et al., 1999).

The activity of HDACs and HATS (Histone Acetyl Transferases) is frequently deregulated in cancer and one of the ways in which

these enzymes are involved in cancer is in the repression of retinoic acid receptor signalling.

The clear involvement of HDACs in the control of cell proliferation and differentiation suggests that aberrant HDAC activity may play a role in cancer. The most direct demonstration that deacetylases contribute to cancer development comes from the analysis of different acute promyelocytic leukemias (APL). In most APL patients, a translocation of chromosomes 15 and 17 (t(15;17)) results in the expression of a fusion protein containing the N-terminal portion of PML gene product linked to most of RAR $\alpha$  (retinoic acid receptor). In some cases, a different translocation (t(11;17)) causes the fusion between the zinc finger protein PLZF and RAR $\alpha$ . In the absence of ligand, the wild type RAR $\alpha$  represses target genes by tethering HDAC repressor complexes to the promoter DNA. During normal hematopoiesis, retinoic acid (RA) binds RAR $\alpha$  and displaces the repressor complex, allowing expression of genes implicated in myeloid differentiation. The RAR $\alpha$  fusion proteins occurring in APL patients are no longer responsive to physiological levels of RA and they interfere with the expression of the RA-inducible genes that promote myeloid differentiation. This results in a clonal expansion of promyelocytic cells and development of leukaemia. *In vitro* experiments have shown that TSA is capable of restoring RA-responsiveness to the fusion RAR $\alpha$  proteins and of allowing myeloid differentiation. These results establish a link between HDACs and oncogenesis and suggest that HDACs are potential targets for pharmaceutical intervention in APL patients. (See, for example, Kitamura et al., 2000; David et al., 1998; Lin et al., 1998).

Furthermore, different lines of evidence suggest that HDACs may be important therapeutic targets in other types of cancer. Cell

lines derived from many different cancers (prostate, colorectal, breast, neuronal, hepatic) are induced to differentiate by HDAC inhibitors (Yoshida and Horinouchi, 1999). A number of HDAC inhibitors have been studied in animal models of cancer. They  
5 reduce tumour growth and prolong the lifespan of mice bearing different types of transplanted tumours, including melanoma, leukaemia, colon, lung and gastric carcinomas, etc. (Ueda et al., 1994; Kim et al., 1999).

10 Thus, although HDAC inhibitors (HDACi) are a promising new class of anti-cancer drug, the molecular basis for their selective growth-inhibitory activity on cancer cells is at present unclear.

15 PRAME was first identified as an antigen in human melanoma that triggers cytotoxic T cell-mediated anti-tumour immune responses (Ikeda et al, 1997). PRAME is also over-expressed in a variety of other human malignancies, including acute and chronic leukemias, non-small-cell lung carcinoma, head and neck cancer,  
20 renal carcinoma, and its expression is prognostic for a poor clinical outcome in breast cancer (Ikeda, 1997; van't Veer 2002; van Baren, 1998; Neumann 1998; Boon, 2003). However, no function for PRAME has been described to date.

25 The present invention demonstrates that PRAME expression inhibits retinoic acid-induced differentiation, growth arrest and apoptosis and that PRAME is, therefore, a dominant repressor, or negative regulator, of RAR signalling. The invention also shows that PRAME suppresses the HDACi-mediated  
30 activation of RAR signalling. These discoveries of a function for PRAME have opened up a new avenue for the treatment of cancer, via the suppression of PRAME, as well as enabling the stratification of subjects prior to treatment with known anti-cancer treatments, such as retinoids and HDACi's.

54236-2

5

Summary of the Invention

In one aspect, the invention provides use of an effective amount of a PRAME inhibitor, in combination with a second agent selected from the group consisting of a retinoid and an HDAC inhibitor (HDACi), in the treatment of a tumour.

In another aspect, the invention provides ab PRAME inhibitor and a second agent selected from the group consisting of a retinoid and an HDAC inhibitor (HDACi) for administration to a subject either simultaneously or serially, in cancer therapy.

10 In another aspect, the invention provides use of an HDAC inhibitor (HDACi) or a retinoid, for treating a tumour in a subject, wherein the subject has received treatment so as to suppress the level of PRAME in the tumour at the time of HDACi or retinoid administration.

15 In another aspect, the invention provides an assay for an inhibitor of an interaction between PRAME and a retinoic acid receptor (RAR) which comprises bringing together: (i) candidate inhibitor; and (ii) a PRAME protein and a RAR protein; and determining if the putative inhibitor is capable of preventing  
20 an interaction between said PRAME and RAR proteins.

In another aspect, the invention provides use of a PRAME inhibitor for treating a tumour in a subject, wherein said subject is receiving treatment with a retinoid or an HDAC inhibitor (HDACi).

25 In another aspect, the invention provides use of a PRAME inhibitor for treating a tumour in a subject, wherein said subject subsequently receives treatment with a retinoid or an HDAC inhibitor (HDACi).

54236-2

6

Brief Description of the Figures

**Figure 1: PRAME is a repressor of RAR signalling.** **a**, 293 cells were transfected with a GAL4-PRAME chimeric construct and a GAL4-luciferase reporter. **b**, 293 cells were transfected as in **a**,  
5 and were treated with PXD101. **c**, Ras<sup>V12</sup> MEFs were transfected with a RA-responsive luciferase reporter (RARE-luc) and either PRAME or empty vector, and treated with RA. **d**, Ras<sup>V12</sup> MEFs were transfected as in **c**, and treated with PXD101. **e**, Ras<sup>V12</sup> MEFs were transfected with RARE-luciferase and either RAR $\alpha$  or empty  
10 vector, and were treated with PXD101.

**Figure 2: PRAME and its interaction with RAR.** **a**, Schematic representation of PRAME. Amino acid residue numbers of the seven NR box motifs are indicated. **b**, B16 melanoma cells were transfected with RARE-luc and either PRAME or PRAME- $\Delta$ LXXLL, and  
15 treated with RA. Average values are of three independent transfections ( $\pm$ s.d.).

**Figure 3: Effects of PRAME expression.** Proliferation curve of A375-PRAME<sup>KD</sup> cells grown in normal medium or medium supplemented with 5  $\mu$ M RA.

20 **Figure 4: PRAME represses RAR signalling.** **a**, B16 melanoma cells were transfected with RARE-luciferase and either PRAME or empty vector and treated with RA. **b**, Ras<sup>V12</sup> MEFs were transfected as

in **a**, and treated with TSA. **c**, B16 melanoma cells were transfected with a RAR $\beta$ 2-promoter luciferase reporter (RAR $\beta$ 2-luc) and either PRAME or empty vector and treated with RA. **d**, *Ras*<sup>V12</sup> MEFs were transfected with a RAR $\beta$ 2-luciferase reporter (R140-luc) or a RAR $\beta$ 2-luciferase reporter with a mutated RARE (M3M7-luc) and either PRAME or empty vector and treated with RA. Average values are of three independent transfections ( $\pm$ s.d.).

**Figure 5: Effects of PRAME expression on RA-signalling in**

**melanoma.** **a**, **b**, FM6 (**a**) and SK23 (**b**) human melanoma cells were transfected with RARE-luciferase and either pRS-PRAME or empty vector and treated with RA. **c**, A375 cells were transfected as in **a**, and treated with PXD101. **d**, B16 melanoma cells were transfected with a p21-promoter luciferase construct and either PRAME or empty vector and treated with RA. Average values are of three independent transfections ( $\pm$ s.d.).

Detailed Description of the Invention

***Inhibitor of PRAME***

An inhibitor of PRAME includes any compound capable of either preventing expression of PRAME or of preventing PRAME when expressed from exerting its normal activity. Normal activity, as used in this respect, refers to any activity performed by the PRAME expression product in the human or animal body. Typically such activities include the repression of transcription and/or interaction with RAR.

A preferred inhibitor of PRAME is an interfering RNA (RNAi). RNA interference is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. RNA interference (RNAi) is a process whereby the introduction of double stranded RNA (dsRNA) into a cell

inhibits gene expression post-translationally, in a sequence dependent fashion. This process is also known as post-transcriptional gene silencing. Current models of RNAi indicate that it is mediated by short (typically 20-25 nucleotides)

5 dsRNAs known as 'small interfering RNAs' (siRNA). It appears that dsRNA is cleaved in the cell to create siRNAs. siRNAs are then incorporated into an RNA-induced silencing complex (RISC), guiding the complex to the homologous endogenous mRNA. The activated RISC then cleaves the mRNA transcript, resulting in  
10 the destruction of the mRNA in a cell which is homologous to the siRNAs. The siRNAs are re-cycled. In this way, a relatively small number of siRNAs can selectively destroy a large excess of cellular mRNA.

15 To induce RNA interference in a cell, dsRNA may be introduced into the cell via a transgene, plasmid or virus which brings about expression of the siRNA in the cell. Alternatively, siRNA may be synthesised and introduced directly into the cell, optionally in the form of a pharmaceutical composition.

20

The complementary strands of the siRNA may be between 10 nucleotides (nt) and 30 nt in length, preferably between 20 nt and 25 nt. Preferably, the siRNA is 20, 21 or 22 nt in length. Generally, the nucleotides form a complementary double strand  
25 which may have short overhangs of one or two nt.

The siRNA sequence may be based on a contiguous sequence of 10-30 nucleotides from the cDNA sequence of PRAME. The human cDNA sequence of PRAME is available GenBank accession no. BC014074  
30 and is shown herein as SEQ ID NO:1. It is known that certain residues of SEQ ID NO:1 are sites of single nucleotide polymorphisms, namely residues 177 (T/C), 621 (C/A), 924 (T/C), 1421 (T/C), 1685 (T/C) and 1966 (T/A) and thus siRNAs designed to target regions including any of these SNPs may include one or

other of the SNP residues, or the siRNA may be a mixture thereof. Preferably however the siRNA will be targeted to a region of the sequence which does not contain a known SNP.

- 5 The siRNA may be used to target a coding or non-coding region of SEQ ID NO:1. The coding region comprises 159 to 1688 of SEQ ID NO:1. A particular region of SEQ ID NO:1 which may be targeted is the 21 nucleotide region of 714 - 734, shown below as SEQ ID NO:2.

10

siRNA molecules may be synthesized using standard solid or solution phase synthesis techniques which are known in the art. Linkages between nucleotides may be phosphodiester bonds or alternatives, for example, linking groups of the formula P(O)S, (thioate); P(S)S, (dithioate); P(O)NR'<sup>2</sup>; P(O)R'; P(O)OR<sup>6</sup>; CO; or  
15 CONR'<sup>2</sup> wherein R is H (or a salt) or alkyl (1-12C) and R<sup>6</sup> is alkyl (1-9C) is joined to adjacent nucleotides through-O-or-S-.

Modified nucleotide bases can be used in addition to the  
20 naturally occurring bases, and may confer advantageous properties on siRNA molecules containing them.

For example, modified bases may increase the stability of the siRNA molecule, thereby reducing the amount required for  
25 silencing. The provision of modified bases may also provide siRNA molecules which are more, or less, stable than unmodified siRNA.

The term 'modified nucleotide base' encompasses nucleotides with  
30 a covalently modified base and/or sugar. For example, modified nucleotides include nucleotides having sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3'position and other than a phosphate group at the 5'position. Thus modified nucleotides may

also include 2'substituted sugars such as 2'-O-methyl- ; 2-O-alkyl ; 2-O-allyl ; 2'-S-alkyl; 2'-S-allyl; 2'-fluoro- ; 2'-halo or 2; azido-ribose, carbocyclic sugar analogues a-anomeric sugars; epimeric sugars such as arabinose, xyloses or lyxoses,  
 5 pyranose sugars, furanose sugars, and sedoheptulose.

Modified nucleotides are known in the art and include alkylated purines and pyrimidines, acylated purines and pyrimidines, and other heterocycles. These classes of pyrimidines and purines are  
 10 known in the art and include pseudoisocytosine, N4,N4-ethanocytosine, 8-hydroxy-N6-methyladenine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5 fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyl uracil, dihydrouracil, inosine, N6-isopentyl-  
 15 adenine, 1- methyladenine, 1-methylpseudouracil, 1-methylguanine, 2,2-dimethylguanine, 2methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyl uracil, 5-methoxy amino methyl-2-thiouracil, 5-methoxycarbonylmethyluracil, 5methoxyuracil, 2  
 20 methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methyl ester, psueouracil, 2-thiocytosine, 5-methyl-2 thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil 5-oxyacetic acid, queosine, 2-thiocytosine, 5-propyluracil, 5-propylcytosine, 5-ethyluracil,  
 25 5ethylcytosine, 5-butyluracil, 5-pentyluracil, 5-pentylcytosine, 2,6,diaminopurine, methylpsuedouracil, 1-methylguanine, 1-methylcytosine.

Alternatively, siRNA molecules or longer dsRNA molecules may be  
 30 made recombinantly by transcription of a nucleic acid sequence, preferably contained within a vector as described below. Such a vector may be one designed to be introduced into a target tumour cell so as to produce an siRNA *in vivo*. Where the siRNA is produced by recombinant means, the two strands of the siRNA may

54236-2

11

be produced in separate transcripts. More desirably however the siRNA may be made in the form of a single transcript which forms a hairpin loop structure comprising a double-stranded siRNA sequence, for example as described in Brummelkamp et al, Science  
5 2002.

Thus it will be understood that an inhibitor of PRAME includes a recombinant vector capable of expressing an siRNA in a target tumour cell. Such a vector may comprise a sequence coding for  
10 the siRNA operably linked to a promoter. The promoter may be any promoter suitable for the transcription of the siRNA, such as a eukaryotic promoter. Such a promoter may be an RNA gene promoter, such as a promoter which produces a small RNA transcript which preferably has a defined 3' end lacking a polyA  
15 tail. A preferred such promoter is the polymerase-III H1 gene RNA promoter.

The vector may be a viral vector, such as an adenovirus, herpes virus, vaccinia virus or retrovirus vector. Various viral  
20 vector systems for delivery to a human or animal subject are known in the art, for example as described in US patent numbers 6,228,844 and 6,339,068. The vector will include the siRNA-encoding sequence operably linked to a promoter, as a construct carried by the vector either in place of a native vector gene or  
25 inserted as additional DNA within the vector.

Further inhibitors of PRAME may be identified using the assay described herein below which forms a further aspect of the present invention.

30

#### ***Inhibitor of HDAC***

HDAC inhibitors suitable for use in the treatment of cancer are known in the art. Typical HDACi include trichostatin A (TSA),

54236-2

12

trapoxin, suberoylanilide hydroxamic acid (SAHA), and phenylbutyrate, which have been reported to act, at least in part, by inhibiting histone deacetylase (see, e.g., Yoshida et al., 1990; Richon et al., 1998; Kijima et al., 1993).

5

Additionally, diallyl sulfide and related molecules (see, e.g., Lea et al., 1999), oxamflatin (see, e.g., Kim et al., 1999; Sonoda et al., 1996), MS-27-275, a synthetic benzamide derivative (see, e.g., Saito et al., 1999; Suzuki et al., 1999; 10 note that MS-27-275 was later re-named as MS-275), butyrate derivatives (see, e.g., Lea and Tulsyan, 1995), FR901228 (see, e.g., Nokajima et al., 1998), depudecin (see, e.g., Kwon et al., 1998), and m-carboxycinnamic acid bishydroxamide (see, e.g., Richon et al., 1998) have been reported to inhibit histone 15 deacetylases. *In vitro*, some of these compounds are reported to inhibit the growth of fibroblast cells by causing cell cycle arrest in the G1 and G2 phases, and can lead to the terminal differentiation and loss of transforming potential of a variety of transformed cell lines (see, e.g., Richon et al., 1996; Kim et 20 al., 1999; Yoshida et al., 1995; Yoshida & Beppu, 1988). *In vivo*, phenylbutyrate is reported to be effective in the treatment of acute promyelocytic leukemia in conjunction with retinoic acid (see, e.g., Warrell et al., 1998). SAHA is reported to be effective in preventing the formation of mammary tumours in 25 rats, and lung tumours in mice (see, e.g., Desai et al., 1999).

A preferred class of inhibitors are those described in the following publications:


Watkins, C., et al., 2002, "Carbamic acid compounds comprising a 30 sulfonamide linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/30879 (PCT/GB01/04326) published 18 April 2002;

Watkins, C., et al., 2002, "Carbamic acid compounds comprising an ether linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/26703 (PCT/GB01/04327) published 04 April 2002;

5 Watkins, C., et al., 2002, "Carbamic acid compounds comprising an amide linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/26696 (PCT/GB01/04329) published 04 April 2002; and

10 Watkins, C., et al., 2003, "Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors," published international (PCT) patent application number W003/082288 (PCT/GB03/01463) published 09 October 2003.

A particularly preferred compound is known as PXD101 (N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide), the structure of which  
15 is:



This compound, or a pharmaceutically acceptable salt thereof,  
20 may be used in accordance with the present invention.

### **Retinoid**

Compounds of retinoid type are compounds with a biological activity profile similar to that of all-trans-retinoic acid or  
25 9-cis-retinoic acid, which compounds themselves may be used in the practice of the invention. These compounds can modify the expression of genes by means of receptors of the retinoic acid family, such as the RARs and RXRS. Thus, retinoids may exhibit activity in the test of differentiation of mouse embryonic  
30 teratocarcinoma cells (F9) (Strickland et al 1983) and/or in the test of inhibition of ornithine decarboxylase after induction with TPA in mice (Verma et al, 1978). These tests show the activities of these compounds in the fields of cell differentiation and cell proliferation, respectively.

54236-2

14

A wide variety of retinoids are known in the art. For example, US patent application 20030055110 describes numerous retinoid compounds. The following compounds in particular were found to have activity of the RAR receptor antagonist type: 4-[4-(6-Methoxymethoxy-4'-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(6-Methoxy-4'-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-(6-Methoxyethoxymethoxy-7-(1-adamantyl)-2-naphthyl]salicylic acid; (E)-4-[4-(5-Methoxymethoxy-4'-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 4-[4-(3-Methoxy-4'-methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; 2-Methoxymethoxy-2'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthal-1-en-2-yl) [1,1,4'1"]terphenyl-4"-carboxylic acid; 4-[4-(4'-Methylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid; and 4-[4-(4'-Propylbiphenyl-2-yl)but-3-en-1-ynyl]benzoic acid.

Retinoid compounds such as these and others which exhibit activity at the RAR receptor (by which is meant causing the receptor to induce expression of a RA-responsive gene, for example the RAR $\beta$  gene as described herein), may be suitable for use in the present invention.

#### ***Treatment of a tumour***

The present invention may be applied to the treatment of a wide variety of tumours, particularly those which are associated with over-expression of HDAC, for example as a result of gene amplification or loss of regulation of the HDAC gene.

Tumours in which such over-expression may occur include melanomas, acute and chronic leukemias, non-small-cell lung carcinoma, head and neck cancer, renal carcinoma, and breast cancer.

By "treatment", it will be understood that this includes any intervention designed to alleviate the condition of the patient, e.g. by slowing down the rate of tumour progression, by providing an adjunct to other tumour therapies including surgery, by stabilizing the tumour or achieving partial or complete remission of the tumour.

**Administration**

The present findings indicate that the use of a PRAME inhibitor (PRAMEi) will allow HDAC inhibitors or retinoids to be used more effectively, where the PRAME inhibitor is administered with the HDACi or retinoid. Where reference is made to the administration of an HDACi or a retinoid, the invention also includes the administration of both.

15

By "simultaneous " administration, it is meant that the PRAMEi and the HDACi (or retinoid) are administered to a subject in a single dose by the same route of administration.

By "separate" administration, it is meant that the PRAMEi and the HDACi (or retinoid) are administered to a subject by two different routes of administration which occur at the same time. This may occur for example where one agent is administered by infusion and the other is given orally during the course of the infusion.

25

By "sequential" it is meant that the two agents are administered at different points in time, provided that the activity of the first administered agent is present and ongoing in the subject at the time the second agent is administered. For example, the PRAMEi may be administered first, such that the amount of PRAME protein in the tumour cells of the subject is reduced at the point in time when the HDACi and/or retinoid is administered.

30

Generally, a sequential dose will occur such that the second of the two agents is administered within 48 hours, preferably within 24 hours, such as within 12, 6, 4, 2 or 1 hour(s) of the first agent.

5

The agents will be formulated appropriately for their desired route of administration. The agent or pharmaceutical composition comprising the agent may be administered to a subject by any convenient route of administration, whether  
10 systemically/ peripherally or topically (i.e., at the site of desired action).

Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including,  
15 e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema);  
20 vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular,  
25 subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.

The amount of a PRAMEi, HDACi and retinoid to be administered will ultimately be at the discretion of the physician taking  
30 into account the age and status of the subject, and the particular activity of the agent being administered.

Administration *in vivo* can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of

administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be  
5 carried out with the dose level and pattern being selected by the treating physician.

For example, where the PRAME is an siRNA, doses of siRNA may be in the range of from 0.001 $\mu$ g to 100g mg/kg body weight per dose.  
10 Doses may be administered daily or at other intervals determined by the physician. Where the siRNA is delivered to the site of a tumour in the form of a vector, the dose may be in the range of from  $10^5$  to  $10^8$  copies of the vector, which where the vector is in the form of a viral vector, may equate to the number of viral  
15 particles. For HDACi compounds the dose may be in the range of from 0.1 to about 250 mg per kilogram body weight of the subject per day. Retinoids may be administered in the range of dosages of the order of from 0.05 to 10 mg/kg/day, preferably 0.1 to 7.5 mg/kg/day, more preferably 0.1 to 2 mg/kg/day, administered once  
20 or, in divided doses, 2 to 4 times per day.

***Administration to prior-treated subject.***

In a particular aspect, the invention relates to the use of an HDACi or a retinoid for the treatment of a novel subject type,  
25 namely a subject in whom the level of expression of PRAME in a tumour present in said subject has been suppressed by medical treatment at the time of HDACi or retinoid treatment.

The suppression of expression of PRAME may have been achieved by  
30 use of a PRAMEi as described herein. The patient will be one in which the PRAMEi has been administered recently enough so as to enhance the efficacy of the HDACi or retinoid, compared to the efficacy without the prior treatment. Desirably, the patient

will have been treated with the PRAMEi within the previous 48, preferably 24, more preferably 12, such as 6, 4, 2 or 1 hour(s).

In one embodiment, the patient may be characterised as a patient  
5 in which PRAME siRNA is present in the body of the patient.

***Stratification and selection of subjects***

The present findings also allow the stratification and/or selection of subjects for treatment with a HDACi or retinoid.

10

In this aspect of the invention, it will be necessary to first establish or obtain data from a cohort (e.g. at least 20) existing tumour patients to determine the level of PRAME expression in their tumour. The level of expression may be  
15 determined at the level of RNA expression, e.g. using RT-PCR, or at the level of protein expression, e.g. using an antibody-based approach. Such methods are known per se in the art. The expression levels will be distributed between low, intermediate and high values. It will be appreciated that what is determined  
20 to be of a low, intermediate and high value will be to some extent an arbitrary designation depending upon the criteria applied by any one particular treatment centre, in a similar manner to, for example, biochemical markers used in prenatal diagnoses. However this does not prevent the method being  
25 practiced to the extent that the levels of PRAME can be determined in new subjects and compared to the collected data to establish predictions or dosings in accordance with the invention as set out herein below.

30 In one aspect, the present invention may be used to predict the effectiveness of a course of treatment with HDACi or a retinoid, or to select patient in which treatment with HDACi or a retinoid is more likely to be effective.

Accordingly in one aspect the invention provides a method comprising:

determining the level of expression of PRAME in a tumour of a subject;

5 comparing said level to the levels previously determined in a cohort of patients; and

treating said patient with a HDACi or a retinoid if said level is indicative of low expression.

10 It will be understood that the step of comparing may be performed on historic data, and that it is not necessary to repeat the determination for that cohort each time the above method is practiced.

15 By "low expression" it is preferably meant a level in the lower one-third, preferably the lower quartile of the distribution of the cohort.

The cohort to which reference is made is desirably matched for  
20 one or more of tumour type, age, sex or severity of disease.

In another aspect the invention provides a method comprising:

determining the level of expression of PRAME in a tumour of a subject;

25 comparing said level to the levels previously determined in a cohort of patients; and

treating said patient with a PRAMEi and one or both of an HDACi or a retinoid if said level is indicative of high expression.

30

By "high expression" it is preferably meant a level in the upper one-third, preferably the upper quartile of the distribution of the cohort.

In a similar manner, the invention may also be used to determine the frequency or amount of HDACi or retinoid administered to a patient, with more frequent or higher doses being administered to subjects with moderate to high levels of PRAME expression.

5

**Assay methods**

In another aspect, the finding that PRAME interacts directly with the RAR provides a novel target for agents capable of modulating the growth, differentiation and vitality of cells.

10

Accordingly, candidate inhibitors of the interaction between PRAME and RAR are identified by a method comprising bringing together:

a candidate inhibitor; and

15 a PRAMEprotein and a RAR protein; and

determining if the candidate inhibitor is capable of preventing an interaction between said PRAME and RAR proteins.

For the purposes of this aspect of the invention, a PRAME  
20 protein will comprise a eukaryotic, preferably mammalian, for example a rodent (e.g. murine) or primate, e.g. human PRAME protein or a fragment thereof capable of forming a complex with a full length wild-type RAR protein, particularly human RAR.

25 Human PRAME protein is encoded by SEQ ID NO:1 shown herein. Proteins from other species may also be used, and obtained for example by homology searches of databases of genome sequences where such are available, or by recombinant molecular DNA techniques such as utilizing all or part of SEQ ID NO:1 as a  
30 probe against a genomic or cDNA library from a species of interest.

Fragments of PRAME will preferably comprise at least one of the seven "LXXLL" sequences identified herein, such as at least 2,

3, 4, 5 or 6 such sequences. Fragments may be at least 100, such as at least 200, e.g. at least 300, for example at least 400 amino acids in size. Fragments of these preferred sizes will desirably contain the above-mentioned preferred numbers of  
5 LXXLL motifs.

For the purposes of this aspect of the invention, a retinoic acid receptor alpha (RAR) protein will comprise a eukaryotic, preferably mammalian, for example a rodent (e.g. murine) or  
10 primate, e.g. human RAR protein or a fragment thereof capable of forming a complex with a full length wild-type PRAME protein, particularly human PRAME. The protein may be the alpha 1 or alpha 2 isoform.

15 A number of different RAR alpha proteins are available on public databases. Human RAR-alpha is SwissProt accession P10276, and murine is SwissProt P11416. The rat alpha 2 isoform is Genbank accession AAC23439.1. Non-mammalian versions of the protein have been characterised in chick (SwissProt Q90966), Xenopus  
20 (SwissProt P51126) and pufferfish (SwissProt Q9W5Z3).

Fragments may be at least 100, such as at least 200, e.g. at least 300, for example at least 400 amino acids in size.

25 Assays according to the invention may be performed in any format available to the person skilled in the art. The precise format of the assay of the invention may be varied by those of skill in the art using routine skill and knowledge.

30 For example, the interaction between a PRAME protein and an RAR may be studied by labelling one with a detectable label and bringing it into contact with the other which has been immobilised on a solid support. Suitable detectable labels include <sup>35</sup>S-methionine which may be incorporated into

recombinantly produced PRAME and/or RAR. The recombinantly produced PRAME and/or RAR may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody.

5

The protein which is immobilized on a solid support may be immobilized using an antibody against that protein bound to a solid support or via other technologies which are known *per se*. A preferred *in vitro* interaction may utilise a fusion protein including glutathione-S-transferase (GST). This may be  
10 immobilized on glutathione agarose beads. In an *in vitro* assay format of the type described above the putative modulator compound can be assayed by determining its ability to modulate the amount of labelled PRAME or RAR which binds to the  
15 immobilized GST-RAR or GST-PRAME, as the case may be. This may be determined by fractionating the glutathione-agarose beads by SDS-polyacrylamide gel electrophoresis. Alternatively, the beads may be rinsed to remove unbound protein and the amount of protein which has bound can be determined by counting the amount  
20 of label present in, for example, a suitable scintillation counter.

Alternatively an antibody attached to a solid support and directed against one of PRAME or RAR may be used in place of GST  
25 to attach the molecule to the solid support. Antibodies against PRAME and RAR may be obtained in a variety of ways known as such in the art, and as discussed herein.

In an alternative mode, one of PRAME and RAR may be labelled  
30 with a fluorescent donor moiety and the other labelled with an acceptor which is capable of reducing the emission from the donor. This allows an assay according to the invention to be conducted by fluorescence resonance energy transfer (FRET). In this mode, the fluorescence signal of the donor will be altered

when PRAME and RAR interact. The presence to a candidate modulator compound which modulates the interaction will increase the amount of unaltered fluorescence signal of the donor.

5 FRET is a technique known per se in the art and thus the precise donor and acceptor molecules and the means by which they are linked to PRAME and RAR may be accomplished by reference to the literature.

10 Suitable fluorescent donor moieties are those capable of transferring fluorogenic energy to another fluorogenic molecule or part of a compound and include, but are not limited to, coumarins and related dyes such as fluoresceins, rhodols and rhodamines, resorufins, cyanine dyes, bimanes, acridines,  
15 isoindoles, dansyl dyes, aminophthalic hydrazines such as luminol and isoluminol derivatives, aminophthalimides, aminonaphthalimides, aminobenzofurans, aminoquinolines, dicyanohydroquinones, and europium and terbium complexes and related compounds.

20

Suitable acceptors include, but are not limited to, coumarins and related fluorophores, xanthenes such as fluoresceins, rhodols and rhodamines, resorufins, cyanines, difluoroboradiazaindacenes, and phthalocyanines.

25

A preferred donor is fluorescein and preferred acceptors include rhodamine and carbocyanine. The isothiocyanate derivatives of these fluorescein and rhodamine, available from Aldrich Chemical Company Ltd, Gillingham, Dorset, UK, may be used to label PRAME  
30 and RAR. For attachment of carbocyanine, see for example Guo et al, J. Biol. Chem., **270**; 27562-8, 1995.

The above assay formats may also be used to determine the ability of a putative modulator compound to modulate the

interaction of PRAME with RAR. Such assays are optionally performed in the presence of a retinoid compound, such as retinoic acid.

- 5 Assays of the invention may also be performed *in vivo*. Such an assay may be performed in any suitable host cell, e.g a bacterial, yeast, insect or mammalian host cell. Yeast and mammalian host cells are particularly suitable.
- 10 To perform such an assay *in vivo*, constructs capable of expressing PRAME and RAR and a reporter gene construct may be introduced into the cells. This may be accomplished by any suitable technique, for example calcium phosphate precipitation or electroporation. The three constructs may be expressed
- 15 transiently or as stable episomes, or integrated into the genome of the host cell.

*In vivo* assays may also take the form of two-hybrid assays wherein PRAME and RAR are expressed as fusion proteins, one

20 being a fusion protein comprising a DNA binding domain (DBD), such as the yeast GAL4 binding domain, and the other being a fusion protein comprising an activation domain, such as that from GAL4 or VP16. In such a case the host cell (which again may be bacterial, yeast, insect or mammalian, particularly yeast

25 or mammalian) will carry a reporter gene construct with a promoter comprising a DNA binding elements compatible with the DBD. The reporter gene may be a reporter gene as disclosed above. The promoters for the genes may be those discussed above.

30

PRAME and RAR and the reporter gene, may be introduced into the cell and expressed transiently or stably.

Candidate inhibitor compounds may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants, microbes or other organisms, which contain several characterised or uncharacterised components, may also be used.

5 Combinatorial library technology (including solid phase synthesis and parallel synthesis methodologies) provides an efficient way of testing a potentially vast number of different substances for the ability to modulate an interaction. Such libraries and their use are known in the art for all manner of  
10 natural products, small molecules and peptides, among others. Many such libraries are commercially available and sold for drug screening programmes of the type now envisaged by the present invention.

15 A further class of candidate inhibitor comprises antibodies or binding fragments thereof which bind a protein target.

Examples of antibody fragments, capable of binding an antigen or other binding partner, are the Fab fragment consisting of the  
20 VL, VH, Cl and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')<sub>2</sub> fragments, a bivalent fragment including two Fab fragments  
25 linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included. An antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display  
30 functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. Such a technique allows the rapid production of antibodies against an antigen, and these antibodies may then be screening in accordance with the invention.

Another class of candidate molecules is peptides, based upon a fragment of the protein sequence to be inhibited. In particular, fragments of the protein corresponding to portions  
5 of the protein which interact with other proteins or with DNA, may be a target for small peptides which act as competitive inhibitors of protein function. Such peptides may be for example from 5 to 20 amino acids in length.

10 The peptides may also provide the basis for design of mimetics. Such mimetics will be based upon analysis of the peptide to determine the amino acid residues or portions of their side chains essential and important for biological activity to define a pharmacophore followed by modelling of the pharmacophore to  
15 design mimetics which retain the essential residues or portions thereof in an appropriate three-dimensional relationship. Various computer-aided techniques exist in the art in order to facilitate the design of such mimetics.

20 Inhibitors obtained in accordance with these aspects of the present invention may be used in methods of treating a cancer in a subject.

The present invention therefore also provides a pharmaceutical  
25 composition comprising an inhibitor of the interaction between PRAME and RAR together with a pharmaceutically acceptable carrier therefor.

Generally, the inhibitor will be formulated with one or more  
30 pharmaceutically acceptable carriers suitable for a chosen route of administration to a subject. For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin,

talcum, glucose, sucrose, magnesium carbonate, and the like may be used. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, a inhibitor and optional pharmaceutical adjuvants in a carrier, 5 such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and 10 the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 15 Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

20

Routes of administration may depend upon the precise condition being treated, though since endothelial cells form the lining of the vasculature, administration into the blood stream (e.g. by i.v. injection) is one possible route.

25

In addition, the present invention provides an inhibitor of the interaction between PRAME and RAR for use in therapy.

Furthermore, the present invention provides the use of an 30 inhibitor of the interaction between PRAME and RAR in the manufacture of a medicament for the treatment of a cancer.

### Methods and Experimental

In order to address the molecular basis for the selective growth-inhibitory activity of HDACi on cancer cells, we performed a functional genetic screen to identify genes that  
5 confer resistance to a small-molecule HDACi, named PXD101 (Plumb et al, 2003). Oncogenic  $RAS^{V12}$ -transformed mouse embryonic fibroblasts ( $RAS^{V12}$ -MEFs) were infected with a high complexity retroviral cDNA expression library derived from human K562 erythroleukemia cells and exposed to 1  $\mu$ M PXD101 for three  
10 weeks. HDACi-resistant colonies appeared at low frequency only after infection with cDNA expression library. Integrated proviruses were mobilized from PXD101-resistant colonies by Moloney virus super-infection as described (Jacobs et al, 2000). After second round selection, cDNA inserts were recovered  
15 by PCR and identified by DNA sequence analysis. Using this approach, we identified full-length cDNAs encoding the human melanoma tumour antigen PRAME (PReferentially expressed Antigen in MElanoma (Ikeda et al, 1997) and Retinoic Acid Receptor alpha ( $RAR\alpha$ ) as cDNAs that allow continuous proliferation in the  
20 presence of 1 $\mu$ M PXD101. PRAME also rescues these cells from growth arrest by a related HDACi, Trichostatin A at a concentration of 0.1  $\mu$ M.

PRAME expression by retroviral infection of  $Ras^{V12}$  MEFs was  
25 compared to endogenous PRAME expression levels in the human melanoma cell lines FM6, SK23, 453A0, A375, FM3 and D10. Cell extracts were immunoblotted for PRAME and CDK4 (as a control). The level of PRAME required to confer resistance to HDACi in the  $RAS^{V12}$ -MEFs is comparable to that seen in several human melanoma  
30 cell lines.

$Ras^{V12}$  MEFs were also transduced with PRAME or  $RAR\alpha$  retrovirus and treated with 1  $\mu$ M PXD101 for 16 hrs. Extracts were

immunoblotted for acetyl-H3, p21, PRAME, RAR $\alpha$  and CDK4 (control). It was found that expression of PRAME or RAR $\alpha$  in RAS<sup>V12</sup>-MEFs did not prevent the increase in histone H3 acetylation nor the well-documented induction of p21<sup>cip1</sup> expression by HDACi-treatment (Richon et al 2000), suggesting that PRAME and RAR $\alpha$  act downstream of HDACs to suppress the effects of the HDACi on cell proliferation.

PRAME was first identified as an antigen in human melanoma that triggers cytotoxic T cell-mediated anti tumour immune responses (Ikeda et al 1997). PRAME is also over-expressed in a variety of other human malignancies, including acute and chronic leukemias, non-small-cell lung carcinoma, head and neck cancer, renal carcinoma, and its expression is prognostic for a poor clinical outcome in breast cancer (Ikeda et al 1997; van 't Veer et al, 2002; van Baren et al, 1998; Nemann et al, 1998, Boon et al, 2003). However, no function for PRAME has been described to date. Since HDAC inhibitors affect gene transcription, we asked if PRAME acts as a repressor or activator of transcription. To test this, we co-transfected a vector in which PRAME is fused to the DNA binding domain of the yeast transcription factor GAL4 (GAL4-PRAME) with a GAL4-luciferase reporter plasmid in human 293 cells. Figure 1a shows that expression of GAL4-PRAME caused a strong and dose-dependent inhibition of gene expression, suggesting that PRAME is a repressor of transcription. Treatment of cells with HDACi did not affect this, indicating that PRAME repression is mostly HDAC-independent (Figure 1b).

Because we identified both PRAME and RAR $\alpha$  in the genetic screen described above, we asked if these two proteins act in the same pathway. To address this, we asked if PRAME affects RAR signalling. We transfected PRAME into RAS<sup>V12</sup>-MEFs together with a reporter gene driven by a Retinoic Acid Responsive Element (RARE-luciferase). Figure 1c shows that PRAME expression

strongly inhibited RA-induced activation of the RA-responsive reporter gene over a wide range of RA concentrations. Similar results were obtained in mouse B16 melanoma cells (Figure 4). PRAME also repressed RAR signalling induced by HDACi treatment (Figure 1d and Figure 4). Importantly, ectopic expression of RAR $\alpha$  also repressed the activation of the RA-responsive reporter gene construct by HDACi (Figure 1e). Thus, both cDNAs that we identified in the genetic screen described above suppress HDACi-mediated activation of the RA-responsive reporter gene. This raises the possibility that suppression of HDACi-induced RA-signalling (Lin et al 1998, and Figure 1c) is one way in which cells can become resistant to HDACi treatment. However, our data do not exclude that RAR $\alpha$  and PRAME act on other pathways to mediate escape from HDACi-induced growth arrest.

To further address the effect of PRAME on RA-signalling we studied *RAR $\beta$* , as this gene contains a RA-responsive element in its promoter (de The et al 1990). To ask if PRAME expression affected the expression of the endogenous *RAR $\beta$*  gene, F9 mouse embryo carcinoma cells were transfected with PRAME or empty vector, treated with  $10^{-7}$  M RA, and immunoblotted for RAR $\beta$ . Average values of three independent transfections were determined. It was found that endogenous RAR $\beta$  protein expression was induced only in parental and mock-transfected F9 cells, but not in PRAME-transfected F9 derivatives. PRAME also repressed RA-induced activation of a RAR $\beta$ 2 promoter-luciferase construct in both *RAS<sup>V12</sup>*-MEFs and B16 melanoma cells (Figure 4). Together, these data indicate that PRAME is a negative regulator of RA-signalling.

The observed effect of PRAME on RAR signalling could result from a physical interaction of PRAME with RAR or from more indirect effects. To ask if PRAME physically interacts with RAR, we

stably expressed a TAP-tagged (Rigaut et al, 1999) PRAME in *RAS<sup>V12</sup>*-MEFs. *Ras<sup>V12</sup>* MEFs were infected with TAP-PRAME, RAR $\alpha$ , or GFP (control) retrovirus and cultured in the presence of 1  $\mu$ M PXD101. TAP-PRAME was functional as it rescued cells from  
5 PXD101-induced growth arrest.

*Ras<sup>V12</sup>* MEFs (MEF) were transduced with TAP-tagged PRAME and expression levels were compared to endogenous PRAME in SK23 and A375 melanoma. Importantly, TAP-PRAME protein levels were  
10 comparable to the levels of endogenous PRAME in the human melanoma cell lines SK23 and A375.

TAP-PRAME was immunoprecipitated (using IgG beads (Rigaut et al, 1999), indicated as anti-TAP) before and after treatment with  
15 1 $\mu$ M RA and precipitates were immunoblotted for RAR $\alpha$ . It was found that endogenous RAR $\alpha$  co-precipitates with TAP-PRAME, both in the absence and presence of RA, indicating that PRAME and RAR $\alpha$  form a ligand-independent complex at protein concentrations seen in human tumours.

20

The amino-acid sequence of PRAME contains seven potential leucine-rich nuclear receptor (NR) boxes (LXXLL motifs (Heery et al, 1997), Figure 2c). Many modulators of nuclear receptor activity interact directly with their target receptors via one  
25 or more of these motifs (Heery et al, 1997; Torchia et al, 1997). To test if these motifs in PRAME are required for inhibition of RAR signalling, we introduced point mutations in PRAME, to change several of the leucine residues in each of the seven NR boxes into valines. The resulting mutant, PRAME-  
30  $\Delta$ LXXLL, was expressed at comparable levels as wild type PRAME (as determined by immunoblotting), but failed to repress RAR signalling (Figure 2b). The mutant did not bind RAR $\alpha$ , when immunoprecipitations as described above were performed. We

conclude that the LXXLL motifs in PRAME are required for modulation of RAR activity.

RA induces proliferation arrest, differentiation and apoptosis  
5 in many cell types. We therefore asked if PRAME expression affected the RA-induced differentiation of F9 mouse embryo carcinoma cells towards parietal endoderm (Strickland and Mahdavi, 1978). F9 cells were stably transfected with PRAME or control vector and individual colonies were selected. In the  
10 absence of RA, the morphology of all transfected cells was the same as that of parental F9 cells. However, F9 cells stably transfected with PRAME or empty vector and treated with  $10^{-7}$  M RA were resistant to RA-induced morphological differentiation and growth arrest. Apart from differentiating, a fraction of F9  
15 cells treated with RA dies by apoptosis (Atencia et al, 1994). PRAME expression in F9 cells also conferred resistance to RA-induced apoptosis as cleaved caspase 3 was apparent in vector controls, but not in PRAME transfectants. We conclude that PRAME expression confers resistance to RA-induced proliferation  
20 arrest, differentiation and apoptosis.

Human melanoma cells often have defects in RA signalling (Atencia et al ,1994; van der Leede et al ,1993). As PRAME is over-expressed in some 90% of melanomas (Ikeda et al, 1997), we  
25 asked if PRAME expression explained their RA-unresponsiveness. To test this, we inhibited PRAME expression in several RA-resistant melanoma cell lines (Demary et al, 2001) through RNA interference. We selected a unique 21-mer sequence in the PRAME transcript for cloning into pRETRO-SUPER (pRS), a vector that  
30 mediates suppression of gene expression through synthesis of short hairpin RNAs having small interfering RNA (siRNA)-like properties (Brummelkamp et al, 2002a; Brummelkamp et al 2002b). 293 cells were transfected with flag-tagged PRAME and pRS-PRAME or pRS empty vector. Extracts were immunoblotted for flag or GFP

(control). In addition, A375 cells were transfected with RARE-luciferase and either pRS-PRAME or empty vector and treated with RA. Average values of three independent transfections were determined. A375-PRAME<sup>KD</sup> cells and control A375 cells were  
5 immunoblotted for PRAME, RAR $\alpha$ , p21, and RAR $\beta$ .

It was found that pRS-PRAME mediates effective decrease of ectopically expressed PRAME as well as endogenous PRAME protein. To ask if knockdown of PRAME restores RA-responsiveness, we co-  
10 transfected A375 human melanoma cells, which express high levels of endogenous PRAME, with pRS-PRAME and a RA-responsive reporter gene construct. The PRAME knockdown greatly enhanced RA-signalling in the A375 cells as determined by using the RARE-luciferase construct. Similar results were found in the SK23 and  
15 FM6 human melanoma cell lines (Figure 5). Melanomas are relatively resistant to treatment with HDACi (Plumb et al, 2003), but A375 cells transfected with pRS-PRAME had enhanced PXD101-induced RAR signalling compared to vector controls (Figure 5).

20 To assess the effect of PRAME knockdown on cell proliferation, we generated stable derivatives of A375 melanoma having shRNA-mediated knockdown of PRAME expression (A375-PRAME<sup>KD</sup>). These A375-PRAME<sup>KD</sup> cells were cultured for 15 days according to the 3T3 protocol. Figure 3 shows that PRAME<sup>KD</sup> significantly  
25 decreased proliferation rates, especially when cultured in the presence of RA. Consistent with the notion that PRAME<sup>KD</sup> restores RA signalling, we found that the known RA target genes RAR $\beta$  and p21<sup>CIP1</sup> (de The et al, 1990, Liu et al 1996) were significantly up-regulated in PRAME<sup>KD</sup> cells, and their induction was further  
30 enhanced by 5  $\mu$ M RA treatment. Consistent with this, a p21 promoter-luciferase reporter was activated by RA in B16 melanoma cells, but its activity was strongly suppressed by PRAME (Figure 5). RAR $\alpha$  is degraded by the proteasome in response to RA signalling (Zhu et al, 1999) and in agreement with this, RAR $\alpha$

protein levels were significantly decreased in PRAME<sup>KD</sup> cells. Together, these data indicate that PRAME is a major regulator of RA-signalling, which contributes to RA-unresponsiveness of human melanomas.

5

The presence of NR boxes in PRAME (Figure 2a) suggests that the interaction between PRAME and RAR $\alpha$  takes place via one or more or more of these motifs. To test if the NR boxes of PRAME are required for binding to RAR and inhibition of RAR signaling,  
10 point mutations were introduced in each of the seven LXXLL motifs in PRAME by changing conserved leucine (L) residues into valines (V). The resulting PRAME mutants were named after the respective NR boxes that were mutated. One additional mutant was made in which all seven LXXLL motifs were mutated, referred to  
15 as PRAME- $\Delta$ LXXLL. MEFs were transfected with RARE-luc and PRAME or PRAME NR box mutants and treated with RA.

Six out of seven PRAME single NR box mutants inhibited RAR signaling to a similar extent as wild-type PRAME except for the  
20 box 7 PRAME-LREVV mutant. This mutant was as defective in repressing RAR signaling as the PRAME mutant in which all 7 NR boxes were mutated. Consistent with this observation, endogenous RAR $\alpha$  failed to co-immunoprecipitate with a TAP-PRAME-LREVV mutant protein. To investigate if the repression function  
25 of PRAME was affected by the LREVV mutation, we tested the effect of cotransfection of a Gal4-PRAME-LREVV fusion protein on expression of the Gal4-luciferase reporter. Gal4-PRAME-LREVV inhibited expression to a similar extent as Gal4-PRAME, indicating that repression was not affected.

30

A mammalian two-hybrid assay was performed in which a wild-type PRAME construct, Gal4-PRAME-LRELL (416-509) or the box 7 mutant Gal4-PRAME-LREVV (416-509) was co-expressed with VP16-RAR $\alpha$  LBD in the presence of RA. Normalized luciferase activities were

determined as the average of three independent transfections. The PRAME wildtype LRELL NR box interacted with VP16-RAR $\alpha$ , but introduction of the LREVV mutation in PRAME disrupted the association. Taken together, these data suggest that an intact  
5 LRELL motif in PRAME is required for binding to RAR $\alpha$  and repression of RAR signaling.

Human melanomas often have defects in RAR signaling (Demary et al., 2001; van der Leede et al., 1993) and PRAME is over-  
10 expressed in 88% of primary melanomas and 95% of melanoma metastases (Ikeda et al., 1997). This raises the possibility that PRAME expression is responsible for their RA-unresponsiveness. To test this hypothesis, we inhibited PRAME expression in three different melanoma cell lines (A375, FM6 and  
15 SK23) through stable RNA interference (Brummelkamp et al., 2002a). Transfection of A375 human melanoma cells with a PRAME-specific shRNA vector (pRS-PRAME) caused a significant decrease in levels of endogenous PRAME. Knockdown of PRAME greatly enhanced RAR signaling in three human melanoma cell lines that  
20 are relatively insensitive to RA. Together, these data support the notion that PRAME expression confers cellular resistance to RA in human melanoma.

To examine the role of PRAME in RA-responsiveness *in vivo*, we  
25 used a human melanoma xenograft model. Nude mice were subcutaneously transplanted with parental A375 into one flank and A375-PRAMEKD cells in the opposite flank and the mice were treated p.o. daily with either 5 mg/kg RA or vehicle only, while tumor volumes were measured weekly. Tumor growth was severely  
30 retarded by RA treatment in PRAMEKD melanomas, but not in parental A375 melanomas that grew in a different anatomical location in the same mice. Together, these data suggest that PRAME functions as a negative regulator of RAR signaling, which contributes to RA-unresponsiveness of human melanomas.

The data presented here indicate that PRAME is a dominant, ligand-independent, repressor of RAR signalling, resulting in a decreased cellular response to RA-driven differentiation, growth arrest and/or apoptosis. PRAME is distinct from the known co-repressors of nuclear receptors such as N-CoR and SMRT, whose interaction with nuclear receptors is lost upon ligand binding (Xu et al 1999). Our data also identify PRAME expression as a novel mechanism by which tumour cells can escape tumour-suppressive RA signalling. In this respect, PRAME expression phenocopies the PML-RAR $\alpha$  and PLZF-RAR $\alpha$  translocations seen in acute promyelocytic leukemia. Hence, melanoma cells and other tumour cells that over-express PRAME have a selective advantage over PRAME-negative cells, which may explain why PRAME expression is retained by tumour cells *in vivo*, despite the fact that its presence elicits a cytotoxic T cell-mediated anti-tumour immune response (Ikeda et al., 1997). Finally, our data suggest a strategy to select subjects that are likely to benefit most from treatment with HDACi compounds.

## Methods.

### ***Reagents, antibodies and plasmid construction***

Full-length PRAME in pcDNA3.1/Neo(+) was a gift from Drs. M. Griffioen and C. Melief (Leiden, The Netherlands). Retroviral PRAME was generated by cloning a BamHI-XhoI PRAME fragment into pMX-IRES-GFP (pMIG). TAP-tagged PRAME was generated by cloning a PCR amplified EcoRI PRAME fragment into pZOME-1-N (Cellzome) and Gal4-PRAME was generated by cloning a BamHI-XbaI PRAME fragment into a GAL4-DBD expression vector. Retroviral RAR $\alpha$  was generated by cloning an EcoRI digested RAR $\alpha$  cDNA into pMX. The PRAME- $\Delta$ LXXLL mutant was made using the QuikChange Site-Mutagenesis kit (Stratagene). PRAME- $\Delta$ LXXLL has multiple of the leucines (L) in the LXXLL motifs changed into valines (V). The

resulting sequences were: LDVVV, VRLL, LDQVV, VQALL, LLAVV, LQSVV, LREVV.

pRS-PRAME was generated by ligating synthetic oligos against the  
 5 target sequence GGTGCCTGTGATGAATTGTTT (SEQ ID NO:2) into pRS in  
 a manner similar to that described previously (Brummelkamp et  
 al, 2002a). The following oligonucleotide sequences were  
 annealed:

10 5'-GATCCCCGGTGCCTGTGATGAATTGTTT *TTCAAGAGAGACAATTCATCACAGGCACCTTTTGGAAA*-3'  
 (SEQ ID NO:3)  
 and

5'-AGCTTTTCCAAAAAGGTGCCTGTGATGAATTGTTT TCTCTTGAAGAACAATTCATCACAGGCACCGGG-3'  
 15 (SEQ ID NO:4)

to provide a double strand with overhanging BamH1 ends. This  
 was ligated into the vector. Expression from the H1-RNA  
 promoter provides a transcript commencing at start of the target  
 20 sequence (5' underlined region in SEQ ID NO:3), through a  
 hairpin loop (*italics* in SEQ ID NO:3 above), and terminating at  
 the end of the complement (3' underlined region of SEQ ID NO:3)  
 of the target sequence, with the addition of a 2 nt overhang.

25 RA-responsive luciferase constructs and RAR $\alpha$  cDNA were kindly  
 provided by Dr. H. Stunnenberg (Nijmegen, The Netherlands). The  
 erythroleukemia retroviral cDNA library was provided by Dr. Koh  
 and Dr. Daley (Cambridge, Massachusetts). All-trans-retinoic  
 acid (ATRA) and TSA were from SIGMA, and PXD101 was provided by  
 30 Topotarget/Prolifix Ltd (Abingdon, UK). Anti-PRAME affinity-  
 purified antibodies were a generous gift from Dr. P. Coulie  
 (Brussels, Belgium) and were generated by immunizing rabbits  
 with peptides FPEPEAAQPMTKKRKVDG (AH-151; SEQ ID NO:6) and  
 CGDRTFYDPEPIL (AH-152; SEQ ID NO:7). Antibodies against RAR $\alpha$   
 35 (C-20), RAR $\beta$  (C-19), p21 (F5), GFP (FL), CDK4 (C-22), and CDK2  
 (H-298) were from Santa Cruz Biotechnologies, anti-acetyl H3 was

from Serotec, anti-Ras (R02120) was from Transduction laboratories, and anti-cleaved caspase-3 (Asp 175) was from Cell Signaling.

#### 5 ***Cell cultures, genetic screen, and colony formation assays***

All cells were cultured in DMEM supplemented with 10% fetal calf serum (FCS). Phoenix packaging cells were used to generate ecotropic retroviruses as described (Serrano et al, 1997). p53<sup>-/-</sup> MEFs were infected with pBabe-Puro-RAS<sup>V12</sup> retrovirus and selected  
10 for puromycin resistance. The resulting RAS<sup>V12</sup>-MEFs were infected with library retroviral supernatants and re-plated at a cell density of 5.10<sup>4</sup> cells/ 10 cm dish 48 hrs after infection. HDAC inhibitor PXD101 (1 µM) or TSA (0.1 µM) was added to the medium 16 hours after reseeding and the medium with HDAC inhibitor was  
15 refreshed every third day.

#### ***Transfections and reporter assays***

Transfections were carried out using the Lipofectamine reagent (Invitrogen), except for Ras<sup>V12</sup> MEFs and Phoenix cells, which  
20 were transfected using calcium phosphate precipitation. RA-based reporter assays were done in DMEM with charcoal-stripped FCS (Hyclone). In reporter assays 0.5 µg of reporter-luciferase, 1 ng CMV-renilla, and 3 µg of the indicated DNA were transfected. RA, PXD101, or TSA was added 24 hrs after transfection and assays  
25 were performed 48 hrs after transfection. In knock-down experiments, RA or PXD101 was added 72 hrs after transfection and assays were performed 96 hrs after transfection. Luciferase activities shown represent ratios between luciferase and renilla internal control values.

30

#### ***Western blotting and co-immunoprecipitation***

Cells were lysed in Ripa buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, and 0.1% SDS) supplemented with protease inhibitors (Complete; Roche) and 0.2 nM PMSF and

proteins were separated on 10-14% SDS-PAGE gels. Proteins were transferred to polyvinylidene difluoride membranes (Immobilon P, Millipore) and Western blots were probed with the indicated antibodies. For TAP (co-)immunoprecipitations cells were lysed  
5 in ELB buffer (0.25 M NaCl, 0.1% NP-40, 50 mM HEPES pH 7.3) supplemented with protease inhibitors and PMSF. Lysates were incubated with IgG-coated sepharose beads (Amersham) to immunoprecipitate TAP and TAP-PRAME (Rigaut et al 1999), indicated as anti-TAP, or with protein A beads and normal mouse  
10 serum (mock IP) for 2 hrs, washed, and separated on SDS-PAGE gels.

#### ***Differentiation and proliferation assays***

F9 cells were stably transfected with PRAME or empty vector and  
15 resistant cells were differentiated in  $10^{-7}$  M RA for 5 days. A375 cells were stably transfected with pRS-PRAME or empty vector and stable clones were cultured according to the 3T3 protocol. Medium with RA was refreshed every 24-48 hrs.

#### ***Mouse tumor xenografts***

Female 5-6 week old athymic BALB-C nude mice (*nu/nu*) were s.c. implanted with  $1 \times 10^6$  cells bilaterally into the axial regions. Each mouse received A375-PRAMEKD cells in its right flank and control A375 cells in its left flank. Mice were randomized into  
25 treatment groups and treated with 5 mg/kg RA or vehicle (ethanol in sunflower oil) p.o. with a 20-gauge intragastric feeding tube daily. Tumor diameter was measured with calipers weekly. The pRS vector which was used to generate A375-PRAMEKD cells is a self-inactivating retroviral vector, to prevent re-activation and  
30 spreading of virus (Brummelkamp et al., 2002a; Brummelkamp et al., 2002b). The experiment was performed twice, with n=20 and n=10 mice and results were similar in both experiments.

References.

- Altucci, L. & Gronemeyer, H. The promise of retinoids to fight against cancer. *Nat Rev Cancer* 1, 181-93. (2001).
- Atencia, R., Garcia-Sanz, M., Unda, F. & Arechaga, J. Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. *Exp Cell Res* 214, 663-7. (1994).
- Boon, K. et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. *Oncogene* 22, 7687-94. (2003).
- Brehm A. et al Retinoblastoma protein recruits histone deacetylase to repress transcription *Nature* 391, 597-601 (1998)
- Brummelkamp, T. R., Bernards, R. & Agami, R. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. *Science* 296, 550-553. (2002a).
- Brummelkamp, T., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* 2, 243-247 (2002b).
- David G. et al Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia associated PLZF protien. *Oncogene* 16(19), 2549-2556 (1998)
- Davie J.R. Covalent modifications of histones: expression from chromatin templates *Curr. Opin. Genet. Dev.* 8 173-178 (1998)
- de The, H., Vivanco-Ruiz, M. M., Tiollais, P., Stunnenberg, H. & Dejean, A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. *Nature* 343, 177-80. (1990).
- Demary, K., Wong, L. & Spanjaard, R. A. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. *Cancer Lett* 163, 103-7. (2001).
- Desai D. et al. Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosaminer 4-(-methylnitros-amino)-1-(3-

- pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice Proc. AACR 40, abstract #2396. (1999)
- Emiliani S. et al Characterisation of a human RPD3 homolog, HDAC3 Proc Natl. Acad. Sci. USA, 95, 2795-2800 (1998)
- Finnin et al Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401, 188-193 (1999)
- Freemantle, S. J., Spinella, M. J. & Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22, 7305-15. (2003).
- Grozinger et al Three proteins define a class of human histone deacetylases related to Hdacp Proc. Natl. Acad. Sci. USA 96, 4868-4873 (1999)
- Heery, D. M., Kalkhoven, E., Hoare, S. & Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (1997).
- Howe L. et al histone acetyltransferase complexes and their link to transcription Crit. Rev. Eukaryot. Gene Expr. 9(3-4) 231-243
- Ikeda, H. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199-208. (1997).
- Jacobs, J. J. et al. Senescence bypass screen identifies TBX2, which represses cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nat Genet 26, 291-299. (2000).
- Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1, 287-99. (2002).
- Kao et al Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression Genes Dev. 14, 55-66 (2000)
- Kijima et al trapoxin an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase J. Biol. Chem. 268, 22429-22435 (1993).

- Kim et al Oxamflatin is is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 18 (15), 2461-2470. (1999).
- Kitamura K et al Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukemic cells with t(11;17) in combination with all-trans retinoic acid. Br. J. Haematol. 108(4), 696-702 (2000)
- Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr, Opin. Genet. Dev 9(1) 44-48 (1999)
- Kuo, M. H. & Allis, C. D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-26. (1998).
- Kwon et al Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase Proc. Natl. Acad. Sci. USA 95, 3356-3361.
- Laherty C.D et al Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression Cell 89(3), 349-356 (1997)
- Lea et al Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Int. J. Oncol. 2, 347-352.
- Lea M.A. and Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deactylase. Anticancer Res. 15(3), 879-883 (1995)
- Lin, R. J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814. (1998).
- Liu, M., Iavarone, A. & Freedman, L. P. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 271, 31723-8. (1996).
- Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1, 194-202. (2001).
- Nakajima et al FR901288, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241, 126-133 (1998)

- Narlikar, G. J., Fan, H. Y. & Kingston, R. E. Cooperation between complexes that regulate chromatin structure and transcription. *Cell* 108, 475-87. (2002).
- Neumann, E. et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? *Cancer Res* 58, 4090-5. (1998).
- Ng H.H. and Bird A. histone deacetylases: silencers for hire *Trends Biochem Sci.* 25(3) 121-126
- Pazin M. J. et al What's up and down with histone deacetylation and transcription? *Cell* 89(3) 325-328
- Plumb, J. A. et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. *Mol Cancer Ther* 2, 721-8. (2003).
- Richon et al Second generation hybrid polar compounds are potent inducers of transformed cell differentiation *Proc. Natl. Acad. Sci. USA* 93, 5705-5708 (1996).
- Richon V et al A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases *Proc. Natl. Acad. Sci. USA* 95, 3003-3007 (1998)
- Richon, V. M., Sandhoff, T. W., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. *Proc Natl Acad Sci U S A* 97, 10014-9. (2000).
- Rigaut, G. et al. A generic protein purification method for protein complex characterization and proteome exploration. *Nat Biotechnol* 17, 1030-2. (1999).
- Saito et al. A synthetic inhibitor of histone deacetylase MS-27-275, with marked in vivo antitumor activity against human tumors. *Proc. Natl. Acad. Sci. USA* 96, 4592-4597 (1999)
- Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 88, 593-602 (1997).

- Sonoda et al. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD. *Oncogene* 13, 143-149 (1996)
- Strickland S et al Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. *Cancer Res* 43(11) 5268-72. (1983)
- Strickland, S. & Mahdavi, V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. *Cell* 15, 393-403 (1978).
- Suzuki et al. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives *J. Med. Chem* 42, 3001-3003 (1999)
- Taunton J. et al A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p *Science* 272 408-411 (1996)
- Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. *Nature* 387, 677-684 (1997).
- Ueda H. et al FR901228, a novel antitumor bicyclic depsipeptide produced by *Chromobacterium violaceum* No. 968.III. Antitumor activities on experimental tumors in mice *J. Antibiot. (Tokyo)* 47 (3), 315-323 (1994).
- van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415, 530-536 (2002).
- van Baren, N. et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. *Br J Haematol* 102, 1376-9. (1998).
- Van den Wyngaert et al Cloning and characterization of human histone deacetylase 8 *FEBS Lett.* 478, 77-83 (2001)
- van der Leede, B. M., van den Brink, C. E. & van der Saag, P. T. Retinoic acid receptor and retinoid X receptor expression in retinoic acid-resistant human tumor cell lines. *Mol Carcinog* 8, 112-22. (1993).

- Verma A.K. et al. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis by vitamin A analogs (retinoids). *Cancer Res.* 38(3) 793-801 (1978)
- Warrell R.P. et al Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. *J. Natl. Cancer Inst.* 90(21) 1621-1625. (1998)
- Watkins, C., et al., 2002, "Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/30879 (PCT/GB01/04326) published 18 April 2002
- Watkins, C., et al., 2002, "Carbamic acid compounds comprising an ether linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/26703 (PCT/GB01/04327) published 04 April 2002
- Watkins, C., et al., 2002, "Carbamic acid compounds comprising an amide linkage as HDAC inhibitors," published international (PCT) patent application number WO 02/26696 (PCT/GB01/04329) published 04 April 2002
- Watkins, C., et al., 2003, "Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors," published international (PCT) patent application number WO03/082288 (PCT/GB03/01463) published 09 October 2003.
- Wong J. et al Distinct requirements for chromatin assembly intrascriptonal repression by thyroid hormone receptor and histone deacetylase *EMBO J.* 17(2), 520-534 (1998)
- Xu, L., Glass, C. K. & Rosenfeld, M. G. Coactivator and corepressor complexes in nuclear receptor function. *Curr Opin Genet Dev* 9, 140-7. (1999).
- Yang W. M. et al Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase family *J. Biol. Chem.* 272, 28001-28007 (1997)
- Yang W.M. et al Transcriptional repression of YY1 is mediated by interaction of a mammalian homolog of the yeast global regulator RPD3 *Proc. Natl. Acad. Sci. USA* 93, 12845-12850 (1996)

- Yoshida and Beppu Reversible arrest of proliferation of rat 3Y1 fibroblasts in both G1 and G2 phases by trichostatin A. Exp. Cell Res. 177, 122-131. (1988)
- Yoshida and Horinouchi, Trichostatin A and leptomycin: inhibition of histone deacetylation and signal dependent nuclear export Ann. N.Y. Acad. Sci. 886, 23-26 (1999)
- Yoshida et al Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function Bioessays 17, 423-430. (1995)
- Yoshida M. et al Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J. Biol. Chem. 265(28), 17174-17179 (1990)
- Yoshida M. et al Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation inducing activity in Friend leukemia cells J. Antibiot. (Tokyo) 43(9), 1101-1106 (1990)
- Zhu, J. et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 96, 14807-12. (1999).

## SEQ ID NO:1 - Human PRAME

```
1  gggaaaccga ctctggggag cagggaggaa cgcgcgctcc agagacaact tcgcggtgtg
61  gtgaactctc tgaggaaaaa cacgtgcggtg gcaacaagtg actgagacct agaaatccaa
121 gcgttggagg tcctgaggcc agcctaagtc gcttcaaaat ggaacgaagg cgtttgtggg
181 gttccattca gagccgatac atcagcatga gtgtgtggac aagcccacgg agacttgtgg
241 agctggcagg gcagagcctg ctgaaggatg aggccctggc cattgccgcc ctggagttgc
301 tgcccaggga gctcttcccg ccaactcttca tggcagcctt tgacgggaga cacagccaga
361 ccctgaaggc aatggtgcag gcctggccct tcacctgcct ccctctggga gtgctgatga
421 agggacaaca tcttcacctg gagaccttca aagctgtgct tgatggactt gatgtgctcc
481 ttgcccagga ggttcgcccc aggaggtgga aacttcaagt gctggattta cggaagaact
541 ctcatcagga cttctggact gtatggtctg gaaacagggc cagtctgtac tcatttccag
601 agccagaagc agctcagccc atgacaaaga agcgaaaagt agatggtttg agcacagagg
661 cagagcagcc cttcattcca gtagagggtg tcgtagacct gttcctcaag gaagggtgct
721 gtgatgaatt gttctcctac ctcattgaga aagtgaagcg aaagaaaaat gtactacgcc
781 tgtgctgtaa gaagctgaag atttttgcaa tgcccatgca ggatatcaag atgatcctga
841 aaatggtgca gctggactct attgaagatt tggaagtgac ttgtacctgg aagctaccca
```

901 ccttgggcgaa attttctcct tacctgggcc agatgattaa tctgcgtaga ctccctcctct  
961 cccacatcca tgcattcttcc tacatttccc cggagaagga agagcagtat atcgcccagt  
1021 tcacctctca gttcctcagt ctgcagtgcc tgcaggctct ctatgtggac tctttatttt  
1081 tccttagagg ccgcctggat cagttgctca ggcacgtgat gaaccccttg gaaaccctct  
1141 caataactaa ctgccggctt tcggaagggg atgtgatgca tctgtcccag agtcccagcg  
1201 tcagtcagct aagtgtcctg agtctaagtg gggtcattgct gaccgatgta agtcccagagc  
1261 ccctccaagc tctgctggag agagcctctg ccaccctcca ggacctggtc tttgatgagt  
1321 gtgggatcac ggatgatcag ctccctggcc tcctgccttc cctgagccac tgctcccagc  
1381 ttacaacctt aagcttctac ggggaattcca tctccatata tgccttgtag agtctcctgc  
1441 agcacctcat cgggctgagc aatctgacct acgtgctgta tcctgtcccc ctggagagtt  
1501 atgaggacat ccatggtacc ctccacctgg agaggcttgc ctatctgcat gccaggctca  
1561 gggagttgct gtgtgagttg gggcggccca gcatggtctg gcttagtgcc aaccctgtc  
1621 ctactgttg ggacagaacc ttctatgacc cggagcccat cctgtgcccc tgtttcatgc  
1681 ctaactagct ggggtgcacat atcaaatgct tcattctgca tacttgagaca ctaaagccag  
1741 gatgtgcatg catcttgaag caacaaagca gccacagttt cagacaaatg ttcagtgtga  
1801 gtgaggaaaa catgttcagt gaggaaaaaa cattcagaca aatgttcagt gaggaaaaaa  
1861 aggggaagtt ggggataggc agatgttgac ttgaggagtt aatgtgatct ttggggagat  
1921 acatcttata gagttagaaa tagaatctga atttctaaag ggagattctg gcttgggaag  
1981 tacatgtagg agttaatccc tgtgtagact gttgtaaaga aactgttgaa aataaagaga  
2041 agcaatgtga aaaaaaaaaa aaaaaaa

## Translation of ORF (SEQ ID NO:5):

1 merrrlrgsi qsryismvsw tsprrlvela gqsllddeal aiaalellpr elfpplfmaa  
61 fdgrhsqtlk amvqawpftc lplgvlmkqg hlhletfkav ldgldvllaq evrprrwklq  
121 vldlrknshq dfwtvwsgrn aslysfpepe aaqpmtkkkrk vdglsteaeq pfipvevlvd  
181 lflkegacde lfsyliekvk rkknvrlrcc kklkifampm qdikmilkmv qldsiedlev  
241 tctwklptla kfspylgqmi nlrrlllshi hassyispek eeqyiaqfts qflslqlqla  
301 lyvdsllflr grldqllrhv mnpletlsit ncrllsegdvm hlsqspsvsq lsvlslsqvm  
361 ltdvspeplq allerasatl qdlvfdecgi tddqllallp slshcsqltt lsfygnsisi  
421 salqslqlhl iglsnlthvl yvplesyed ihgtlhlerl aylharlrel lcelgrpsmv  
481 wlsanpcphc gdrtfydpep ilcpcfmpn

# **DEMANDES OU BREVETS VOLUMINEUX**

**LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVETS  
COMPREND PLUS D'UN TOME.**

**CECI EST LE TOME \_\_1\_\_ DE \_\_2\_\_**

NOTE: Pour les tomes additionels, veuillez contacter le Bureau Canadien des Brevets.

---

# **JUMBO APPLICATIONS / PATENTS**

**THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE  
THAN ONE VOLUME.**

**THIS IS VOLUME \_\_1\_\_ OF \_\_2\_\_**

NOTE: For additional volumes please contact the Canadian Patent Office.

54236-2

48

CLAIMS:

1.           Use of an effective amount of a PRAME inhibitor, in combination with a second agent selected from the group consisting of a retinoid and an HDAC inhibitor (HDACi), in the  
5 treatment of a tumour.
2.           The use according to claim 1, wherein the PRAME inhibitor is a small interfering RNA (siRNA) that inhibits expression of PRAME.
3.           The use according to claim 1 or 2, wherein said HDACi  
10 is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide.
4.           The use according to claim 1, 2 or 3, wherein said tumour is a melanoma.
5.           A PRAME inhibitor and a second agent selected from the group consisting of a retinoid and an HDAC inhibitor  
15 (HDACi) for administration to a subject either simultaneously or serially, in cancer therapy.
6.           The PRAME inhibitor and the second agent according to claim 5, wherein said cancer therapy is treatment of a melanoma.
- 20 7.           The PRAME inhibitor and the second agent according to claim 5 or 6, wherein said PRAME inhibitor is a small interfering RNA (siRNA) that inhibits expression of PRAME.
8.           The PRAME inhibitor and the second agent according to claim 5, 6 or 7, wherein said HDACi is N-hydroxy-3-(3-  
25 phenylsulfamoyl-phenyl)-acrylamide.

54236-2

49

9. The use according to claim 1, wherein the use of the HDACi or the retinoid is simultaneous or sequential to the use of the PRAME inhibitor in the treatment of the tumour.

10. Use of an HDAC inhibitor (HDACi) or a retinoid, for  
5 treating a tumour in a subject, wherein the subject has received treatment so as to suppress the level of PRAME in the tumour at the time of HDACi or retinoid administration.

11. Use according to claim 9 or 10 wherein said tumour is a melanoma.

10 12. An assay for an inhibitor of an interaction between PRAME and a retinoic acid receptor (RAR) which comprises bringing together:

(i) a candidate inhibitor; and

(ii) a PRAME protein and a RAR protein; and

15 determining if the putative inhibitor is capable of preventing an interaction between said PRAME and RAR proteins.

13. The use according to any one of claims 1 to 4, wherein the tumour is insensitive to the HDACi administered alone or to retinoic acid administered alone.

20 14. Use of a PRAME inhibitor for treating a tumour in a subject, wherein said subject is receiving treatment with a retinoid or an HDAC inhibitor (HDACi).

15. Use of a PRAME inhibitor for treating a tumour in a subject, wherein said subject subsequently receives treatment  
25 with a retinoid or an HDAC inhibitor (HDACi).




Figure 1

Figure 2




Figure 3




Figure 4




Figure 5

